Perspectives on Checkpoint Inhibitors in Adv/Met Lung Cancer - priME Oncology
Expert Perspectives
Expert Perspectives

Perspectives on Checkpoint Inhibitors in Adv/Met Lung Cancer

Evaluating Current and Emerging Strategies in the Fight Against Advanced/Metastatic Lung Cancer

Not a member of My prIME? Join now for instant access.

Listen to a brief overview on the optimal use of checkpoint inhibitors for patients with advanced/metastatic lung cancer and learn the current and emerging use in the treatment of non-small cell lung cancer (NSCLC). Furthermore, explore the practical considerations on using PD-L1 testing in clinical care and how to manage immune-related adverse events. This activity features a summarized presentation with downloadable slides from our satellite symposium held in conjunction with ESMO 2017 in Madrid, Spain.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Oct 19, 2017

Expiration Date

Oct 19, 2018

  • Enriqueta Felip, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Jürgen R. Fischer, MDKlinik Löwenstein gGmbH
    Löwenstein, Germany
  • Marina Garassino, MDFondazione IRCCS - Istituto Nazionale dei Tumori
    Milan, Italy
  • Naiyer Rizvi, MDNew York-Presbyterian Hospital
    Columbia University Medical Center
    New York, New York, United States
  • Current uses of checkpoint inhibitor therapy in the treatment of NSCLC
  • Biomarkers in clinical practice: Benefits and limitations
  • Early identification and optimal management of immune-related adverse events (irAEs)
  • Safety and efficacy of emerging checkpoint inhibitors in NSCLC

This educational activity is specifically designed to meet the needs of medical oncologists, pulmonologists, and other multidisciplinary specialists involved in the treatment of patients with NSCLC.

After successful completion of this educational activity, participants should be able to:

  • Assess recent data on the efficacy/safety of checkpoint inhibitor therapy for the treatment of NSCLC
  • Implement appropriate treatments for NSCLC that incorporate the use of checkpoint inhibitors
  • Analyze recent efficacy and safety data on emerging checkpoint inhibitors, alone and in combination with other agents, in the treatment of NSCLC
  • Describe the benefits and limitations of using PD-L1 as a biomarker to guide treatment selection when managing NSCLC
  • Develop management strategies to address irAEs related to the use of checkpoint inhibitors

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.